How much revenue does Fuan Pharmaceutical (Group) make?

Fuan Pharmaceutical (Group) reported 1.74 billion CNY in revenue for fiscal year 2025, down 27.3% from 2.39 billion CNY in fiscal year 2024. In Q1 2026 revenue was 407.49 million CNY.

Where does Fuan Pharmaceutical (Group) make most of its revenue?

East China: 37% of revenue by region in fiscal year 2024, followed by Central China (21%).

What companies are similar to Fuan Pharmaceutical (Group)?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Lionco Pharmaceutical Group Co.,Ltd. (603669.SS), Teyi Pharmaceutical Group Co.,Ltd (002728.SZ), Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ), Kexing Biopharm Co., Ltd. (688136.SS).

Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ) Stock

About Fuan Pharmaceutical (Group) Co., Ltd.

Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China and internationally. It offers APIs; intermediates; and FDFs, such as anti-tumor, specialty drugs, antibiotics, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) C...

At a glance

Fuan Pharmaceutical (Group) reported revenue of 1.74 billion CNY for fiscal year 2025, down 27.3% from fiscal year 2024, and net income of 77.00 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 407.49 million CNY, down 12.9% from a year before. East China was its largest region in fiscal year 2024, with 37% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.